[[Whitepaper]] Development of Robust Processes for Large Scale Antibody-Drug Conjugation

Antibody-drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. ADCs are composed of a moncolonal antibody (mAb) conjugated to a drug molecule via a linker. The use of mAbs results in the delivery of the cytotoxic payload to only the targeted cell type, and because of this ADCs have shown promise as an effective site-specific cancer therapy (1). Two ADC’s, Kadcylca ® (Genentech/Roche) and Adcetris ® (Seattle Genetics), have been approved by the FDA for use in Her2-positive metastatic breast cancer and relapsed Hodgkin’s Lymphoma or systemic anaplastic large cell lymphoma respectively.

Download the whitepaper by MabPlex now >>

There are more than 50 ADC candidates currently in clinical development, with more than 10 entering Phase II and III clinical trials. However, large-scale production of ADCs has been hampered by a number of factors, including the lack of efficient and consistent conjugation of antibody to the desired toxic compound; inconsistent antibody internalization; and unstable linkers that release the toxin prior to the arrival at the target tissue. MabPlex offers state of the art solutions to these problems to allow robustly, large-scale production of ADCs with predictable and consistent conjugation efficiency using a variety of linkers.

Download the whitepaper >>

If you’re interested in learning more about MabPlex and their solutions to large-scale ADC production challenges, visit them at Booth 11 at Americas Antibody Congress 2017 , May 23-24 at the Hilton San Diego Resort and Spa in San Diego, CA